Extractables & Leachables CDMO Services

Extractables and leachables work answers a direct pharmaceutical question: what chemical species can come out of materials that contact the product, and what actually migrates into the drug product under real storage, processing, and use conditions?

This matters because a drug product is never alone. It touches glass, elastomers, polymers, adhesives, coatings, lubricants, filters, tubing, bags, syringes, closures, labels, device components, and manufacturing surfaces. These materials may release organic compounds, inorganic elements, oligomers, additives, antioxidants, plasticisers, residual monomers, silicone species, metals, or degradation products.

A programme can fail because an elastomer leachable appears late in stability, a plastic additive migrates into formulation, a surfactant increases extraction, a biologic binds to silicone oil, a nasal spray pump introduces unexpected residues, a BFS resin has an unsuitable leachable profile, or analytical methods miss low-level compounds with toxicological relevance.

That is why Extractables & Leachables CDMO Services require materials science, analytical chemistry, container closure knowledge, toxicological risk assessment, stability study design, forced extraction, migration assessment, GMP documentation, and disciplined regulatory strategy.

Sophia supports E&L programmes through risk assessment, material review, extractables study design, leachables study design, LC-MS, GC-MS, ICP-MS interface, volatile and semi-volatile compound assessment, elemental impurity review, toxicological evaluation, stability-linked leachables monitoring, documentation, and European execution through state-of-the-art facilities in Spain and Switzerland.

The objective is direct: identify, measure, assess, document, and control material-derived chemical risk before it becomes a regulatory or patient-safety problem.

Why Extractables and Leachables Development Matters

Extractables and leachables matter because pharmaceutical products contact materials throughout manufacturing, storage, shipping, administration, and use. A container closure system or single-use component can be technically convenient and still introduce chemical risk if material compatibility is not understood.

E&L programmes may support:

Sterile injectable products
Ophthalmic products
Inhalation and nasal products
Blow-fill-seal products
Prefilled syringes
Cartridges and autoinjector systems
Elastomer stoppers and plungers
Plastic containers
Glass containers and coatings
Single-use systems
Tubing, bags, filters, and connectors
Drug-device combination products
Biologics and peptides
Complex injectables
Clinical and commercial CMC packages

The technical challenge is that E&L risk depends on product, material, contact time, temperature, solvent strength, pH, surfactants, preservatives, sterilisation, processing conditions, and route of administration. A low-risk oral product and a chronic inhalation product do not carry the same toxicological concern.

A serious Extractables & Leachables CDMO Services programme therefore builds a risk-based bridge between material chemistry, analytical detection, product stability, toxicology, and regulatory documentation.

History

The history of extractables and leachables testing developed from the broader recognition that packaging and manufacturing materials can affect medicine quality. Early pharmaceutical packaging focused heavily on containment, protection, and convenience. Glass bottles, rubber closures, metal tubes, plastic containers, and later prefilled systems were selected to hold products safely, but analytical tools were limited.

As analytical chemistry improved, packaging stopped being treated as invisible. Chromatography, mass spectrometry, elemental analysis, spectroscopy, and trace-level detection made it possible to identify compounds migrating from materials into drug products. The rise of plastics, elastomers, coatings, adhesives, and single-use manufacturing systems made the issue more important. Materials were no longer simple passive barriers; they became complex chemical systems.

Sterile injectables, inhalation products, ophthalmics, and biologics made the field especially serious. These products may be administered directly into sensitive tissues, lungs, eyes, or systemic circulation. Low-level leachables can therefore matter more than they might in lower-risk dosage forms. Long shelf life, chronic use, high surface-area contact, and formulation surfactants can increase concern.

Single-use bioprocessing also changed the field. Bags, tubing, filters, connectors, and polymeric components became common in biologics manufacturing. These systems reduce cleaning burden and increase flexibility, but they also introduce new extractables and leachables questions.

Modern E&L work now sits at the intersection of materials science, toxicology, analytical chemistry, pharmaceutical development, and regulatory strategy. It is not merely a test. It is a structured argument that the product-contact system is chemically understood and patient risk is controlled.

That is the territory for Extractables & Leachables CDMO Services: making the invisible chemistry of pharmaceutical materials visible, measurable, and defensible.

The Science of Extractables & Leachables

Extractables are compounds that can be pulled from a material under exaggerated or aggressive laboratory conditions. Leachables are compounds that actually migrate into the drug product under normal or reasonably foreseeable conditions of manufacture, storage, administration, or use.

Important technical attributes include:

Material composition
Polymer type
Elastomer formulation
Additives and antioxidants
Plasticisers
Residual monomers
Oligomers
Silicone species
Adhesives and inks
Elemental impurities
Solvent strength
pH
Surfactants
Contact time
Temperature
Sterilisation method
Surface area-to-volume ratio
Route of administration
Toxicological threshold
Analytical uncertainty

Extractables studies explore what might come out. Leachables studies confirm what does come out. Both are needed when material risk is meaningful.

Sophia builds Extractables & Leachables CDMO Services around the relationship between product, material, method, exposure, detection, toxicology, and documentation.

She treats E&L as product-contact chemistry, not paperwork.

Technical Development Notes

E&L development often fails when studies are designed too generically. A standard solvent panel may produce data, but not necessarily useful product-specific risk understanding. The study design should reflect the actual material, dosage form, route, contact time, temperature, formulation chemistry, patient exposure, and regulatory risk.

For example, a surfactant-containing biologic in a prefilled syringe may extract compounds differently from a simple aqueous small molecule in a glass vial. A nasal spray pump may introduce residues from multiple moving polymer and elastomer components. An inhalation product may require especially low concern thresholds because respiratory exposure can be sensitive. A BFS product may need resin-linked leachables assessment over stability. A single-use bioprocess bag may require evaluation of process-contact duration, temperature, and solvent exposure.

Sophia’s E&L development model links risk assessment, materials mapping, study design, analytical screening, compound identification, toxicological evaluation, stability monitoring, and regulatory documentation. This gives sponsors a top-tier European and global CDMO platform for programmes where product-contact materials must be chemically understood before approval, scale-up, or transfer.

An E&L package succeeds when it does not merely list peaks, but explains risk.

Product Types Supported

Sophia supports Extractables & Leachables CDMO Services across feasibility, risk assessment, analytical study design, stability-linked leachables monitoring, toxicological review, GMP documentation, and technology transfer.

Product types may include sterile injectables, biologics, monoclonal antibodies, peptides, vaccines, ophthalmic products, nasal sprays, inhalation products, blow-fill-seal products, prefilled syringes, cartridges, autoinjector systems, vials, elastomer closures, plungers, tubing, filters, bags, connectors, single-use systems, drug-device combination products, and complex injectable products.

Programme types may include E&L gap assessment, material inventory, extractables study design, leachables study design, method selection, unknown identification, toxicological assessment, stability monitoring, regulatory response support, supplier-change assessment, device-component assessment, and global tech transfer.

A stopper is not a syringe barrel. A BFS resin is not a silicone-coated syringe. A nasal spray pump is not a vial closure. The material system must define the study.

Best-Fit Programme Types

Sophia is especially suited for sponsors with E&L programmes requiring European execution, container closure evaluation, prefilled syringe assessment, BFS resin assessment, inhalation or nasal product risk review, ophthalmic packaging evaluation, single-use system assessment, biologics material compatibility, regulatory response support, or global technology transfer.

The strongest fit is a programme where product-contact materials influence safety, stability, administration, or regulatory risk. This may include a biologic moving into a syringe, a sterile product changing stopper supplier, a nasal product requiring pump assessment, an inhalation product with low exposure thresholds, or a BFS product entering late-stage development.

Sophia’s Extractables & Leachables CDMO Services are built for sponsors who need chemical-risk judgement, not just analytical output.

Materials Mapping and Risk Assessment

Sophia supports materials mapping and E&L risk assessment. This may include container closure review, component inventory, supplier documentation review, material-of-construction assessment, contact pathway mapping, surface-area calculation, contact duration, temperature, route-of-administration risk, patient exposure, dose frequency, and study justification.

Materials mapping is the first discipline. Sponsors need to know what the product contacts directly and indirectly. This may include primary packaging, secondary-contact components, processing materials, filters, tubing, storage bags, filling needles, plungers, lubricants, coatings, and device parts.

Risk assessment should prioritise components by contact intensity and patient relevance. A high-contact elastomer closure may deserve more attention than a low-contact external housing. A chronic inhalation product may require more conservative thinking than a low-frequency topical product.

The study begins by knowing where the product has been touched.

Extractables Study Design

Sophia supports extractables study design for pharmaceutical materials. This may include solvent selection, exaggerated conditions, reflux or incubation conditions, temperature, time, surface-area-to-volume ratio, polar and non-polar solvent systems, pH conditions, volatile screening, semi-volatile screening, non-volatile screening, elemental analysis, and compound identification strategy.

Extractables studies should be aggressive enough to reveal possible migrants, but not so unrealistic that the data become misleading. Solvent systems should bracket product chemistry. Temperature and time should challenge the material while preserving interpretability. Analytical methods should cover volatile, semi-volatile, non-volatile, organic, and inorganic species as appropriate.

The goal is not to punish the material. The goal is to understand its chemical potential.

Leachables Study Design

Sophia supports leachables study design for real drug product conditions. This may include stability-linked testing, time-point selection, storage condition selection, final container closure testing, placebo comparison, product-matrix effects, method sensitivity, unknown identification, trend analysis, and toxicological threshold comparison.

Leachables studies must evaluate what actually migrates into the product. The formulation may invite certain compounds into solution through wetting, pH, surfactants, preservatives, solvents, ionic strength, and prolonged contact. The material may respond slowly, releasing trace species over time as the product rests against it. The analytical method must be sensitive enough to catch that quiet migration without overcalling noise.

This is the controlled intimacy of pharmaceutical packaging: product and material held together over time, under pressure from storage, temperature, and chemistry. What passes from one into the other must be known, measured, and judged.

Leachables are not theoretical. They are the chemistry of contact made visible.

Analytical Methods and Compound Identification

Sophia supports analytical methods and compound identification for Extractables & Leachables CDMO Services. This may include GC-MS, LC-MS, ICP-MS, headspace GC-MS, HS-GC-FID interface, IC interface, UV methods, CAD or ELSD interface, targeted methods, non-targeted screening, accurate mass assessment, library matching, retention index, reference standard confirmation, semi-quantitation, and method validation or qualification.

E&L analytics must cover different chemical classes. Volatile organic compounds, semi-volatiles, non-volatiles, oligomers, polymer additives, antioxidants, slip agents, catalysts, metals, and silicone species may require different methods.

Unknown identification is often the hardest part. A peak is not a conclusion. The compound must be tentatively identified, confirmed where possible, quantified or estimated, and assessed toxicologically.

The analytical package must turn unknowns into evidence.

Toxicological Assessment and Safety Evaluation

Sophia supports toxicological assessment and safety evaluation for E&L programmes.

This may include compound identification review, exposure estimation, route-specific risk assessment, threshold comparison, impurity qualification interface, genotoxicity concern review, permitted exposure assessment, uncertainty management, and regulatory justification.

Toxicology depends on exposure. A compound detected at low levels may be acceptable for one route and unacceptable for another. Daily dose, duration, patient population, route, product volume, and compound class all matter.

Unknowns create special difficulty. When a compound is unidentified or only tentatively identified, conservative assumptions may be needed. Better analytical identification can reduce unnecessary toxicological uncertainty.

A good toxicological assessment does not dramatise every peak. It separates signal from risk.

Container Closure, Device, and Single-Use Systems

Sophia supports E&L strategy for container closures, devices, and single-use systems.

This may include vials, stoppers, plungers, syringe barrels, needle shields, cartridges, BFS containers, nasal pumps, inhalation devices, ophthalmic containers, tubing, filters, bags, connectors, mixing systems, and filling assemblies.

Single-use systems are especially important in biologics manufacturing because the product may contact polymeric components during upstream, downstream, hold, filtration, or filling steps. These components can introduce process-related leachables before the product reaches final packaging.

Drug-device products add further complexity. Adhesives, springs, lubricants, coatings, dose-delivery components, and storage-contact parts may all need evaluation.

The product’s chemical history includes every material-contact step.

Stability-Linked Leachables Monitoring

Sophia supports stability-linked leachables monitoring. This may include long-term stability, accelerated stability, refrigerated storage, frozen storage where relevant, in-use stability, inverted storage, stressed orientation, light exposure, temperature cycling, shipping stress, and late-stage leachables trending.

Leachables may not appear immediately. Some increase over time. Some rise with temperature. Some appear only after sterilisation, ageing, or formulation interaction.

Some remain stable but become toxicologically relevant because of cumulative exposure.

Stability-linked monitoring connects the E&L programme to real shelf-life behaviour. It helps show whether the final product remains chemically compatible with its container closure system.

A product is not compatible on day one only. It must remain compatible through expiry.

GMP, Quality, and Regulatory Documentation

Sophia supports GMP and GMP-like documentation for Extractables & Leachables CDMO Services, including risk assessments, material inventories, supplier documentation, study protocols, extractables reports, leachables reports, analytical method records, compound identification summaries, toxicological assessments, stability protocols, specifications where relevant, deviation handling, change control, data integrity records, and regulatory response packages.

Documentation should explain why materials were assessed, how studies were designed, what methods were used, which compounds were found, how exposure was estimated, how risk was judged, and how the product-contact system is controlled.

For E&L, the regulatory file must be a coherent argument. Data without rationale can create more questions than answers.

A strong E&L CDMO delivers chemical risk control, not just chromatograms.

Technology Transfer and Supplier Change Support

Sophia supports technology transfer and supplier change support for E&L programmes.

This may include component comparison, supplier documentation review, resin change assessment, stopper change assessment, syringe change assessment, tubing or filter change review, comparability strategy, bridging study design, analytical transfer, toxicology update, stability update, and regulatory documentation.

Technology transfer can expose material changes that seem minor but alter risk. A new elastomer formulation, resin grade, moulding process, sterilisation method, lubricant, adhesive, or coating can change extractables or leachables.

Sophia’s European execution model supports sponsors seeking disciplined E&L assessment, reliable documentation, global supply readiness, and controlled transfer into clinical or commercial manufacturing networks.

European Facilities, Spain, and Switzerland

E&L programmes require materials science, trace analytical chemistry, toxicological judgement, stability design, GMP systems, documentation discipline, and regulatory credibility. Sophia’s European model, supported by state-of-the-art facilities in Spain and Switzerland, gives sponsors a serious platform for extractables and leachables assessment.

Spain supports applied product-contact mapping, study coordination, sample generation, stability execution, analytical interface, and manufacturing-linked documentation.

Switzerland adds precision analytics, compound identification discipline, toxicological review interface, high-control product culture, and European pharmaceutical credibility.

This supports Sophia’s position as a top-tier European and global CDMO platform for sponsors who need E&L work developed with technical seriousness, not checkbox packaging theatre.

No invisible material risk. No unexplained peak. No container closure system without chemical evidence.

Why Sophia for Extractables & Leachables CDMO Services

Sophia supports E&L programmes through risk assessment, material mapping, extractables study design, leachables monitoring, analytical testing, toxicological evaluation, stability, European facility execution, and global technology transfer.

The service includes:

Extractables and leachables programme review
Container closure, device, BFS, syringe, vial, stopper, tubing, filter, bag, and single-use system support
Materials mapping and product-contact risk assessment
Extractables study design and forced extraction strategy
Leachables study design and stability-linked monitoring
LC-MS, GC-MS, ICP-MS, headspace GC-MS, and compound identification interface
Toxicological assessment and exposure-based risk evaluation
Supplier change, technology transfer, and comparability support
GMP/GMP-like documentation support
Spain and Switzerland-linked European execution
Regulatory-ready documentation
Global pharmaceutical tech transfer

The platform is suited to sponsors who need E&L development that is materials-aware, analytically serious, toxicology-linked, documented, and internationally positioned.

Technical Service Summary

Sophia provides Extractables & Leachables CDMO Services for pharmaceutical container closure systems, prefilled syringes, cartridges, vials, elastomer stoppers, BFS products, ophthalmics, nasal sprays, inhalation products, sterile injectables, biologics, single-use systems, tubing, filters, bags, drug-device products, GMP documentation, stability, and technology transfer.

Relevant technical needs include material inventory, risk assessment, extractables study design, leachables study design, LC-MS, GC-MS, ICP-MS, headspace analysis, volatile compounds, semi-volatiles, non-volatiles, elemental impurities, unknown identification, toxicological assessment, exposure estimation, stability-linked monitoring, supplier change assessment, regulatory documentation, CMC support, and global tech transfer.

The service is intended for programmes where material compatibility, analytical chemistry, toxicology, stability, GMP quality, and regulatory strategy must operate together.

FAQ: Extractables & Leachables CDMO Services

1. What are Extractables & Leachables CDMO Services?

Extractables & Leachables CDMO Services support assessment of chemical species that can come from pharmaceutical materials, container closure systems, devices, and single-use systems into drug products.

2. What is the difference between extractables and leachables?

Extractables are compounds that can be extracted from materials under exaggerated conditions. Leachables are compounds that actually migrate into the drug product under normal or relevant use conditions.

3. What products need E&L assessment?

Sterile injectables, biologics, inhalation products, ophthalmics, nasal sprays, prefilled syringes, BFS products, drug-device products, and single-use systems commonly require E&L assessment.

4. What materials are assessed?

Materials may include glass, elastomers, plastics, polymers, adhesives, coatings, silicone oil, tubing, filters, bags, stoppers, plungers, syringe components, cartridges, and device parts.

5. What analytical methods are used?

Methods may include GC-MS, LC-MS, ICP-MS, headspace GC-MS, targeted assays, non-targeted screening, volatile testing, semi-volatile testing, non-volatile testing, and elemental analysis.

6. Why is toxicological assessment important?

Toxicological assessment estimates whether detected or potential compounds create patient risk based on exposure, route of administration, dose, duration, compound identity, and uncertainty.

7. Can Sophia support prefilled syringe E&L?

Yes. Sophia supports syringe-related E&L assessment, including glass, elastomers, plungers, silicone oil, tungsten interface, needle shields, coatings, and stability-linked leachables.

8. Can Sophia support BFS E&L?

Yes. Sophia supports BFS resin and container assessment, extractables study design, leachables monitoring, stability linkage, and regulatory documentation.

9. Why are inhalation products high concern?

Inhalation products can have sensitive exposure routes and low concern thresholds. Device components, pumps, plastics, elastomers, and formulation-contact parts require careful assessment.

10. What should sponsors provide to begin an E&L project?

Useful starting information includes dosage form, formulation, route, dose, container closure system, materials list, supplier documents, stability plan, contact conditions, clinical stage, and regulatory questions.

11. Why can surfactants increase leachables risk?

Surfactants can improve wetting or solubilisation of material-derived compounds, increasing the chance that certain leachables migrate into the formulation.

12. Why can leachables appear late in stability?

Migration can be time- and temperature-dependent. Some compounds accumulate slowly, appear after material ageing, or increase under accelerated storage conditions.

13. Why is unknown identification difficult?

Unknowns may be low-level, structurally complex, poorly represented in libraries, matrix-interfered, or only tentatively identifiable without reference standards.

14. Why can supplier changes trigger E&L work?

A supplier change can alter resin grade, additives, moulding, sterilisation, elastomer formulation, lubricant, adhesive, or coating, which may change the E&L profile.

15. Why is E&L more than analytical testing?

E&L requires risk assessment, study design, compound identification, toxicological evaluation, stability linkage, material control, and regulatory justification. Testing alone is not enough.

Conclusion

Sophia provides Extractables & Leachables CDMO Services for programmes where material compatibility, analytical chemistry, toxicology, stability, GMP quality, and regulatory documentation must be developed together.

The work requires material mapping, extractables studies, leachables monitoring, unknown identification, toxicological assessment, supplier-change control, documentation, and technology transfer.

Through state-of-the-art infrastructure in Spain and Switzerland, Sophia supports E&L development for European and global pharmaceutical sponsors seeking controlled, scalable, technically credible material-contact risk assessment.

Email our team at info@sophiacdmo.com